Net profit also surged 21.45% year-on-year to ₹668 crore from last year’s ₹550 crore. The bottomline was also higher than CNBC-TV18 poll of ₹481 crore.
Alkem Labs’ Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) rose 21.35% from the same quarter a year earlier to ₹739 crore, while a CNBC-TV18 poll was working with a ₹578 crore figure.EBITDA margins for the quarter saw a 190 basis points expansion from last year to 21.9%, which was higher than the CNBC-TV18 estimate of 18%.
Sales from India business rose 12% year-on-year to ₹2,265 crore, while the US business sales grew 8.8% YoY to ₹698 crore.
“Our performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile. These results reflect the disciplined execution of our strategy, focused investments, and a deliberate pivot toward value-accretive products and markets with a sharper focus on EBITDA. We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions,” said Dr. Vikas Gupta, CEO of Alkem.
Shares of Alkem Laboratories Ltd. are trading 6.68% higher after the results announcement at ₹5,168. The stock has risen 10% over the last six months.
